Haemato AG (HAEK.HM) stock: key figures, P/E, revenue and dividend

Health Care · Germany · ISIN DE000A289VV1

Price

13.00 EUR

Market cap

67.98 m EUR

P/E (2022)

8.30

P/S (2022)

0.27

Dividend yield

0.31 %

Net margin

3.30 %

Return on equity (ROE)

5.57 %

Return on assets (ROA)

4.64 %

Haemato AG financials

Fiscal year	2021	2022
Revenue	285.04 m EUR	248.14 m EUR
Gross profit	30.73 m EUR	21.61 m EUR
Operating income	11.16 m EUR	8.30 m EUR
EBIT	9.78 m EUR	10.84 m EUR
Net income	6.53 m EUR	8.19 m EUR
Diluted EPS – continuing operations	1.25 EUR	1.57 EUR

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Haemato AG

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO brand, and cosmetics under the brand M1 SELECT, as well as supplies third party-products. It serves clinics, pharmacies, wholesalers, and medical test centers. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany. HAEMATO AG operates as a subsidiary of M1 Kliniken AG.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.